Republicans question legality of potential settlements for insurers

Republicans on the House Energy and Commerce Committee have asked for HHS to explain how the agency plans to settle lawsuits from health insurers over the multi-billion dollar shortfall in the Affordable Care Act’s risk corridor program.

The letter to HHS Secretary Sylvia Burwell followed comments from CMS Acting Administrator Andy Slavitt, who said Sept. 14 the agency is “open to discussing resolution of claims” related to the risk corridor program. At least five insurers have sued HHS over being paid only 12.6 percent of the amount insurers requested for the first year the ACA exchanges were open, leaving a $2.5 billion shortfall which will require using funds from 2015 transfers, pushing back that year’s payments.

The Republicans’ letter blamed the shortfall on the Obama administration, saying it both promised the program would be budget neutral and assured the insurance companies they would get 100 percent of the funds they requested to cover for significant losses in the first years of the exchanges.

By settling the lawsuits, the Republicans argued the administration would be bypassing Congress, using funds set aside for legal settlements instead of asking legislators for an appropriation.

“Since Congress acted twice to protect taxpayer dollars by prohibiting the use of federal funds to make up for any shortfall in risk corridor payments, the committee is concerned about the administration’s intent to use any federal funds to settle the suits brought by the insurance companies,” the Republicans wrote.

The members ended by requesting CMS turn over additional documents and information by Oct. 4. Among what they’re asking for is a list of all insurers which are planning on suing over the risk corridor payments, which insurers have asked about settlements, who at CMS has discussed settlements with the U.S. Department of Justice and if both departments believe it’s legal to use funds for legal settlements in this case.

 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.